SCHEMBL17508362

SCHEMBL17508362

Clc1nc(-c2cc3ccccc3c3ccccc23)c2nccnc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 3/20 0.41
CCR8 P51685 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
ALDH1A1 P00352 7/20 0.40
CYP11B1 P15538 1/20 0.39
LMNA P02545 4/20 0.37
MAPT P10636 4/20 0.37
MAPK1 P28482 2/20 0.37
CYP3A4 P08684 2/20 0.37
PMP22 Q01453 2/20 0.37
APEX1 P27695 1/20 0.37
NISCH Q9Y2I1 1/20 0.37
HIF1A Q16665 3/20 0.33
TSHR P16473 2/20 0.33
HSD17B10 Q99714 2/20 0.33
HPGD P15428 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
CASP1 P29466 1/20 0.33
RPS6KA5 O75582 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17508371 0.84 ALDH1A1 (0.41) CCR1CCR8L3MBTL1ALDH1A1LMNA
SCHEMBL17508370 0.84 CYP11B1 (0.43) CCR1CCR8L3MBTL1ALDH1A1CYP11B1
SCHEMBL18688232 0.81 CCR1 (0.46) CCR1CCR8L3MBTL1ALDH1A1CYP11B1
SCHEMBL27997637 0.79 CYP11B1 (0.41) CCR1CCR8L3MBTL1ALDH1A1CYP11B1
SCHEMBL17508361 0.75 MAPK9 (0.41) ALDH1A1CYP11B1LMNAMAPTNISCH
SCHEMBL3782353 0.74 KDM4E (0.53) L3MBTL1ALDH1A1LMNAMAPTMAPK1
SCHEMBL30731308 0.73 KDM4E (0.53) L3MBTL1ALDH1A1CYP11B1LMNAMAPT
SCHEMBL15860243 0.73 KDM4E (0.53) L3MBTL1ALDH1A1CYP11B1LMNAMAPT
SCHEMBL17522834 0.72 KDM4E (0.50) L3MBTL1ALDH1A1LMNAMAPTMAPK1
SCHEMBL17522835 0.72 ALDH1A1 (0.42) L3MBTL1ALDH1A1LMNAMAPTNISCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9676767-B2 Indoloacridine-containing derivative, preparation process and use thereof, and organic luminescent device BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-06-13 US disclosed
US-9676767-B2 Indoloacridine-containing derivative, preparation process and use thereof, and organic luminescent device BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-06-13 US disclosed
US-9676767-B2 Indoloacridine-containing derivative, preparation process and use thereof, and organic luminescent device BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-06-13 US disclosed
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2016-02-18 US disclosed
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2016-02-18 US disclosed
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE BOE TECHNOLOGY GROUP CO., LTD. (CN) 2016-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046621-A1 INDOLOACRIDINE-CONTAINING DERIVATIVE, PREPARATION PROCESS AND USE THEREOF, AND ORGANIC LUMINESCENT DEVICE AHR, CDYL, SLC18A1 CCR1 4109/4885CCR8 3753/4885L3MBTL1 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.